Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1330P represents a processed pseudogene derived from the U6 small nuclear RNA gene family. Pseudogenes are non-functional copies of genes, often created by retrotransposition events. The U6 snRNA pseudogenes have been amplified in the genome by LINE-1 (L1) retrotransposition mechanisms and typically lack intronic sequences and display scattered mismatches compared to the parental gene[1]. These pseudogenes are prevalent in vertebrate genomes and mark retrotransposition activity, but there is no evidence they encode a protein, participate in canonical biological processes, or are involved in disease. The functional U6 snRNA is essential for mRNA splicing in the spliceosome, but its processed pseudogenes like RNU6-1330P are generally transcriptionally silent and considered functionless evolutionary relics[3][4].
None; no drugs target this molecule or pseudogene
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1330, pseudogene (RNU6-1330P).